stockrow
Saturday 7 November 2026
Export DRTS’s income statement to Excel — free account
Alpha Tau Medical Ltd.
DRTS Healthcare Biotechnology
- EPS
- −100.0%
- Free cash flow
- −30.4%
- Total debt
- +12.8%
Quarter to June 2026, against a year earlier
13.73
0.43
+3.23%
Follow DRTS
Alert me
Alpha Tau Medical Ltd. (DRTS) P/E ratio
Alpha Tau Medical Ltd. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NKTR Nektar Therapeutics compare | n/m |
| DRTS Alpha Tau Medical Ltd. | n/m |
| MNKD MannKind Corporation compare | n/m |
| URGN Urogen Pharma compare | n/m |
| SLN Silence Therapeutics PLC Sponsored ADR compare | n/m |
| GHRS GH Research PLC compare | n/m |
| LBRX LB Pharmaceuticals Inc compare | n/m |
| AVLN Avalyn Pharma Inc. compare | n/m |
| OMER Omeros Corporation compare | 9.8× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)